美瑞健康(02327.HK)擬日本組合資拓工業大麻
美瑞健康國際(02327.HK)公布,與日本龍舞簽訂一份不具法律約束力的諒解備忘錄,雙方有意在日本成立一家合資公司以從事CBD(大麻二酚)等大麻素霧化技術的研發和利用,推動霧化電子器械等有益健康相關產品在日本及國際市場的研發、生產和銷售。公司將持有合資51%股權。
同時,公司有權分兩輪投資其旨在中國市場拓展霧化產品的關聯公司-認購深圳龍舞10%股權。首輪認購6%股權,對價金額約827萬人民幣;及以不超過5億人民幣的投資後估值再認購深圳龍舞4%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.